E2F Transcription Factor 8 (E2F8) Antibody
357.5€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
E2F Transcription Factor 8 (E2F8) Antibody
Category
Primary Antibodies
Provider
Abbexa
Reference
abx122347
Tested Applications
ELISA, WB, IHC
Description
Rabbit Polyclonal against the E2F8 protein.
Documentos del producto
Instrucciones
Data sheet
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Target: E2F Transcription Factor 8 (E2F8) Immunogen: Recombinant fragment corresponding to 206-464 AA of human E2F8. |
| Host | Rabbit |
| Reactivity | Human |
| Assay Type | Concentration: Lyophilized form: Not applicable. After reconstitution: 1 mg/ml. |
| Recommended Dilution | ELISA: 1/20000 - 1/80000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Observed MW | Observed MW: 94 kDa |
| Purification | Purified by antigen affinity column chromatography. |
| Size 1 | 100 µg |
| Size 2 | 1 mg |
| Form | Lyophilized |
| Tested Applications | ELISA, WB, IHC |
| Buffer | Prior to lyophilization: 1% BSA and 0.02% NaN3. |
| Availability | Shipped within 7-15 working days. |
| Storage | Store at -20 °C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| NCBI Accession | BC028244 |
| Alias | E2F-8 |
| Background | Antibody anti-E2F8 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Background
E2F8 is another atypical member of the E2F family that functions as a transcriptional repressor, particularly during the late stages of the cell cycle. Like E2F7, E2F8 contains two DNA-binding domains but lacks a transactivation domain, allowing it to bind and repress E2F target genes involved in cell proliferation, DNA replication, and mitosis. E2F8 is upregulated during the G2/M phase and works in conjunction with E2F7 to suppress aberrant cell cycle progression and regulate genomic stability. E2F8 is critical for embryonic development, angiogenesis, and placental formation, where it regulates the proliferation of endothelial cells and trophoblasts. Dysregulation of E2F8 has been linked to cancer progression, as its overexpression promotes tumor growth, metastasis, and chemoresistance. Knockout models reveal defects in placental vascularization, embryonic lethality, and impaired cell cycle regulation, emphasizing its importance in cell cycle control, development, and cancer biology.